Saturday, October 3, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleCrunchbase News

US Startup Funding Slows Sharply In March

View original at news.crunchbase.com
Crunchbase News - Funding Ma Title: US Startup Funding Slows Sharply In March Date: 2026-03-23 17:36 Source: https://news.crunchbase.com/business/us-startup-funding-slows-march-2026-data/ <p><span style="font-weight: 400;">After a rollicking start in </span><a href="https://news.crunchbase.com/ai/global-vc-investment-s…
Opening lines of the source · Crunchbase News · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • A $110 billion funding round will likely take years, not weeks or months, to be topped

    60% confidence

  • This month's funding deceleration is mostly a U.S. phenomenon

    60% confidence

  • The slowdown is almost entirely due to fewer giant AI megarounds closing this month

    60% confidence

  • American companies raised just around $13 billion in seed through growth-stage funding in March 2026 so far

    60% confidence

  • US startup funding slowed dramatically in March 2026 after strong January and February

    60% confidence

  • European startup funding hit its highest point of the year in March 2026

    60% confidence

  • February's U.S. funding tally will remain one for the record books

    60% confidence

  • Early- and seed-stage dealmaking in March is on track to come in close to the prior two months' levels

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com